Furthermore, Tim‐3 is also known to be expressed on the surface of CD8+ tumor‐infiltrating lymphocytes in tumor‐bearing mice (Sakuishi et al., 2010), which suggests its potential as a therapeutic target in various diseases. This evidence concerns the gene HAVCR2 and neoplasm.